[
  {
    "ts": null,
    "headline": "Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer",
    "summary": "Gilead Sciences (NasdaqGS:GILD) recently announced positive results from its ASCENT-03 study, leading to a significant role in treating metastatic triple-negative breast cancer. This likely bolstered investor confidence, as evident by a 6% increase in its share price over the past week. Amid broader market declines, with major indexes experiencing downturns due to renewed trade worries and tech sector declines, Gilead's news appears to have countered these negative trends. The pharmaceutical...",
    "url": "https://finnhub.io/api/news?id=21bcc71059de888b08dbbad35464a3f5bf0ea7db02d60fff02505972b911428b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748021058,
      "headline": "Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer",
      "id": 134674294,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (NasdaqGS:GILD) recently announced positive results from its ASCENT-03 study, leading to a significant role in treating metastatic triple-negative breast cancer. This likely bolstered investor confidence, as evident by a 6% increase in its share price over the past week. Amid broader market declines, with major indexes experiencing downturns due to renewed trade worries and tech sector declines, Gilead's news appears to have countered these negative trends. The pharmaceutical...",
      "url": "https://finnhub.io/api/news?id=21bcc71059de888b08dbbad35464a3f5bf0ea7db02d60fff02505972b911428b"
    }
  },
  {
    "ts": null,
    "headline": "Gilead (GILD) to Acquire HOOK for $10 million",
    "summary": "Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million. Gilead Sciences Inc. (NASDAQ:GILD) commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. GILD is only purchasing HOOK’s antiviral programs, specifically the “HB-400” & “HB-500”. The company first […]",
    "url": "https://finnhub.io/api/news?id=3966ebfbfc794619585a8b54b21389fa84a90849d3733b40d631810a90261f66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748011341,
      "headline": "Gilead (GILD) to Acquire HOOK for $10 million",
      "id": 134674297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million. Gilead Sciences Inc. (NASDAQ:GILD) commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. GILD is only purchasing HOOK’s antiviral programs, specifically the “HB-400” & “HB-500”. The company first […]",
      "url": "https://finnhub.io/api/news?id=3966ebfbfc794619585a8b54b21389fa84a90849d3733b40d631810a90261f66"
    }
  },
  {
    "ts": null,
    "headline": "ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors",
    "summary": "FOSTER CITY, Calif., May 23, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy). The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for PD-1/PD-L1 inhibitors, m",
    "url": "https://finnhub.io/api/news?id=c1a06a42b427ae2a4700f7dc05fbf1014f2461f0c86aa9d709ee9e53f2848731",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748003400,
      "headline": "ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors",
      "id": 134658698,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., May 23, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy). The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for PD-1/PD-L1 inhibitors, m",
      "url": "https://finnhub.io/api/news?id=c1a06a42b427ae2a4700f7dc05fbf1014f2461f0c86aa9d709ee9e53f2848731"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of Trodelvy",
    "summary": "Gilead Sciences, Inc. announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy®? . The study met its primary endpoint, demonstrating a highly statistically significant and...",
    "url": "https://finnhub.io/api/news?id=99a2a695439c26071b9186e055045614f8ea4937d4fe28bc4b9d2095548dafa1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747994726,
      "headline": "Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of Trodelvy",
      "id": 134660781,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences, Inc. announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy®? . The study met its primary endpoint, demonstrating a highly statistically significant and...",
      "url": "https://finnhub.io/api/news?id=99a2a695439c26071b9186e055045614f8ea4937d4fe28bc4b9d2095548dafa1"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Are So Bad, They’re Good. What to Buy Now.",
    "summary": "Healthcare Stocks Are So Bad, They’re Good. What to Buy Now.",
    "url": "https://finnhub.io/api/news?id=be40883f19bb45f9eda62075704d2003c83870c5c275ca68bc64590e4d843100",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747994220,
      "headline": "Healthcare Stocks Are So Bad, They’re Good. What to Buy Now.",
      "id": 134662722,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Healthcare Stocks Are So Bad, They’re Good. What to Buy Now.",
      "url": "https://finnhub.io/api/news?id=be40883f19bb45f9eda62075704d2003c83870c5c275ca68bc64590e4d843100"
    }
  },
  {
    "ts": null,
    "headline": "Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?",
    "summary": "Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain. Click to read why VRTX is a Buy.",
    "url": "https://finnhub.io/api/news?id=6723b8b091a6b77518608ce5f37e5c1eb72d9fc217c1ae3d6a56933a9ad8073b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747993615,
      "headline": "Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?",
      "id": 134660926,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2174377045/image_2174377045.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain. Click to read why VRTX is a Buy.",
      "url": "https://finnhub.io/api/news?id=6723b8b091a6b77518608ce5f37e5c1eb72d9fc217c1ae3d6a56933a9ad8073b"
    }
  },
  {
    "ts": null,
    "headline": "ASCENT-03 - Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors",
    "summary": "Gilead Sciences Inc: * ASCENT-03: TRODELVY® DEMONSTRATES HIGHLY STATISTICALLYSIGNIFICANT & CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSIONFREE SURVIVAL IN PATIENTS WITH FIRST-LINE...",
    "url": "https://finnhub.io/api/news?id=5642c1a6d91954d01f7d920a549210f25e92d078bb38b7e072eb1869bbba437f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747990217,
      "headline": "ASCENT-03 - Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors",
      "id": 134658199,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences Inc: * ASCENT-03: TRODELVY® DEMONSTRATES HIGHLY STATISTICALLYSIGNIFICANT & CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSIONFREE SURVIVAL IN PATIENTS WITH FIRST-LINE...",
      "url": "https://finnhub.io/api/news?id=5642c1a6d91954d01f7d920a549210f25e92d078bb38b7e072eb1869bbba437f"
    }
  }
]